Menninga Nathan J, Rohde Kalynn A, Schlei Zachary W, Katers Krista M, Weber Ashley K, Brokhof Marissa M, Hawes Donald S, Radford Kelly L, Francois Mary L, Cornwell Richard D, Benca Ruth, Hayney Mary S, Dopp John M
Pharmacy Practice Division, School of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.
University of Wisconsin Hospitals and Clinics, University of Wisconsin-Madison, Madison, WI, USA.
Prog Transplant. 2016 Jun;26(2):149-56. doi: 10.1177/1526924816640980. Epub 2016 Apr 13.
Complications following lung transplantation are common and significantly reduce quality of life, and increase morbidity and mortality. Increasing evidence suggests sleep disorders are prevalent following lung transplantation, but factors associated with their development are not known.
We sought to evaluate the prevalence of restless legs syndrome (RLS) in a lung transplant population and determine if a relationship exists between RLS and exposure to immunosuppressant medications.
DESIGN, SETTING, AND PARTICIPANTS: Subjects were recruited through the University of Wisconsin Hospital and Clinics Lung Transplant Clinic (N = 125). Participants (N = 81) completed sleep questionnaires, including the four RLS diagnostic criteria, insomnia severity index, and Sheehan disability scale. Cumulative tacrolimus exposure was determined in 62 subjects by calculating an area under the curve (AUC) to assess for a relationship with restless legs syndrome.
Prevalence of RLS was 35 percent. Cumulative mean ± SEM tacrolimus exposure was similar in patients with RLS versus those without RLS (17446 ± 1855 ng days/mL vs. 15303 ± 1643 ng days/mL, respectively; p = 0.42). Insomnia severity index scores (12.5 ± 1.0 vs 6.8 ± 0.7, p < 0.0001) and Sheehan disability scores (7.8 ± 1.3 vs 3.6 ± 0.6, p = 0.003) were significantly higher in those with vs those without RLS symptoms, respectively.
Our data confirms increased prevalence of RLS following lung transplantation reported by previous studies. RLS symptoms were not related to estimated tacrolimus exposure. Predictors of RLS following lung transplantation need to be further investigated to better identify and control RLS symptoms and reduce associated insomnia and disability.
肺移植后的并发症很常见,会显著降低生活质量,并增加发病率和死亡率。越来越多的证据表明,睡眠障碍在肺移植后很普遍,但与其发生相关的因素尚不清楚。
我们试图评估肺移植人群中不宁腿综合征(RLS)的患病率,并确定RLS与免疫抑制药物暴露之间是否存在关联。
设计、地点和参与者:通过威斯康星大学医院和诊所肺移植诊所招募受试者(N = 125)。参与者(N = 81)完成了睡眠问卷,包括四项RLS诊断标准、失眠严重程度指数和希恩残疾量表。通过计算曲线下面积(AUC)来确定62名受试者的他克莫司累积暴露量,以评估与不宁腿综合征的关系。
RLS的患病率为35%。有RLS的患者与无RLS的患者的他克莫司累积平均±标准误暴露量相似(分别为17446±1855纳克·天/毫升和15303±1643纳克·天/毫升;p = 0.42)。有RLS症状者的失眠严重程度指数评分(12.5±1.0对6.8±0.7,p < 0.0001)和希恩残疾评分(7.8±1.3对3.6±0.6,p = 0.003)分别显著高于无RLS症状者。
我们的数据证实了先前研究报道的肺移植后RLS患病率增加。RLS症状与估计的他克莫司暴露无关。需要进一步研究肺移植后RLS的预测因素,以更好地识别和控制RLS症状,并减少相关的失眠和残疾。